Ypsomed - Public Comps and Valuation Multiples

Ypsomed Overview

About Ypsomed

Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.

Founded

2003

HQ

Employees

2.8K+

Website

ypsomed.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $918M

LTM EBITDA $334M

EV

$5.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ypsomed Financials

As of September 2025, Ypsomed reported last 12-month revenue of $918M and EBITDA of $334M.

In the same period, Ypsomed generated $380M in LTM gross profit and $179M in net income.

See Ypsomed valuation multiples based on analyst estimates

Ypsomed P&L

In the most recent fiscal year, Ypsomed reported revenue of $931M and EBITDA of $237M.

Ypsomed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ypsomed valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$918M	XXX	$931M	XXX	XXX	XXX
Gross Profit	$380M	XXX	$363M	XXX	XXX	XXX
Gross Margin	41%	XXX	39%	XXX	XXX	XXX
EBITDA	$334M	XXX	$237M	XXX	XXX	XXX
EBITDA Margin	36%	XXX	25%	XXX	XXX	XXX
EBIT	$212M	XXX	$140M	XXX	XXX	XXX
EBIT Margin	23%	XXX	15%	XXX	XXX	XXX
Net Profit	$179M	XXX	$109M	XXX	XXX	XXX
Net Margin	20%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$287M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ypsomed including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $918M. EBITDA for the last twelve months was $334M. In the most recent fiscal year, Ypsomed achieved $931M in revenue and $237M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$918M	Analyst estimates available to subscribers	$931M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$380M	Analyst estimates available to subscribers	$363M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	41.4% gross margin	Analyst estimates available to subscribers	39.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$334M	Analyst estimates available to subscribers	$237M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	36.4% EBITDA margin	Analyst estimates available to subscribers	25.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$212M	Analyst estimates available to subscribers	$140M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	23.1% EBIT margin	Analyst estimates available to subscribers	15.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$179M	Analyst estimates available to subscribers	$109M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	19.5% net profit margin	Analyst estimates available to subscribers	11.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$287M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ypsomed

This financial data table provides comprehensive performance metrics for Ypsomed, a company based in Switzerland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Ypsomed generated $918M in revenue over the last twelve months.
The company achieved $334M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $380M.
Net income over the last twelve months reached $179M.

Fiscal Year Performance

In the most recent fiscal year, Ypsomed reported $931M in total revenue.
Fiscal year EBITDA was $237M.
The company maintained a gross profit margin of 39.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 25.5%.
Net profit margin reached 11.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ypsomed. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ypsomed Stock Performance

Ypsomed has current market cap of CHF 4.2B (or $5.3B), and EV of CHF 4.5B (or $5.5B).

Market Cap Evolution

Ypsomed Stock Data

As of October 17, 2025, Ypsomed's stock price is CHF 310 (or $385).

See Ypsomed trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.5B	$5.3B	XXX	XXX	XXX	XXX	$12.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ypsomed Valuation Multiples

Ypsomed's trades at 6.4x EV/Revenue multiple, and 24.3x EV/EBITDA.

See valuation multiples for Ypsomed and 15K+ public comps

Ypsomed Financial Valuation Multiples

As of October 17, 2025, Ypsomed has market cap of $5.3B and EV of $5.5B.

Equity research analysts estimate Ypsomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ypsomed has a P/E ratio of 29.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.3B	XXX	$5.3B	XXX	XXX	XXX
EV (current)	$5.5B	XXX	$5.5B	XXX	XXX	XXX
EV/Revenue	6.0x	XXX	6.4x	XXX	XXX	XXX
EV/EBITDA	16.6x	XXX	24.3x	XXX	XXX	XXX
EV/EBIT	26.2x	XXX	42.0x	XXX	XXX	XXX
EV/Gross Profit	14.6x	XXX	n/a	XXX	XXX	XXX
P/E	29.4x	XXX	49.6x	XXX	XXX	XXX
EV/FCF	-70.4x	XXX	-42.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ypsomed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ypsomed Margins & Growth Rates

Ypsomed's last 12 month revenue growth is -3%

Ypsomed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Ypsomed's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ypsomed's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ypsomed and other 15K+ public comps

Ypsomed Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-3%	XXX	1%	XXX	XXX	XXX
EBITDA Margin	36%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	14%	XXX	29%	XXX	XXX	XXX
Rule of 40	23%	XXX	23%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	28%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	24%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial